Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
Research ArticleTheranostics

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer

Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn and Frederik L. Giesel
Journal of Nuclear Medicine June 2019, 60 (6) 801-805; DOI: https://doi.org/10.2967/jnumed.119.227967
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Flechsig
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Lindner
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Labidi Abderrahim
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Altmann
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Mier
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Adeberg
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Heidelberg Institute for Radiation Oncology, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrik Rathke
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Röhrich
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hauke Winter
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
6Department of Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter K. Plinkert
7Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Marme
8Department Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany
9Department Obstetrics and Gynecology, University Hospital Mannheim, Mannheim, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Lang
10Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Ulrich Kauczor
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
11Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Jäger
12Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Germany
13Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Debus
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Heidelberg Institute for Radiation Oncology, Heidelberg, Germany
14Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik L. Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (>12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax < 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax < 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

  • FAPI
  • breast cancer
  • colorectal cancer
  • lung cancer
  • PET/CT

Footnotes

  • Published online Apr. 6, 2019.

  • © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (6)
Journal of Nuclear Medicine
Vol. 60, Issue 6
June 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Jun 2019, 60 (6) 801-805; DOI: 10.2967/jnumed.119.227967

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K. Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Jun 2019, 60 (6) 801-805; DOI: 10.2967/jnumed.119.227967
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
  • Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX
  • Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
  • The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
  • Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
  • Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
  • Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
  • The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
  • Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
  • The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
  • High-resolution positron emission microscopy of patient-derived tumor organoids
  • Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
  • Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
  • FAP: The Next Billion Dollar Nuclear Theranostics Target?
  • A Conversation Between Uwe Haberkorn and Johannes Czernin
  • Google Scholar

More in this TOC Section

Theranostics

  • Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
  • Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Show more Theranostics

Clinical

  • Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
  • Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Show more Clinical

Similar Articles

Keywords

  • FAPI
  • Breast cancer
  • Colorectal cancer
  • lung cancer
  • PET/CT
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire